<DOC>
	<DOCNO>NCT02143648</DOCNO>
	<brief_summary>The primary objective study evaluate effect two dos nalbuphine HCl ER tablet change baseline bad itch Numerical Rating Scale ( NRS ) hemodialysis patient moderate severe uremic pruritus evaluate safety tolerability study population .</brief_summary>
	<brief_title>Study Nalbuphine HCl ER Tablets Hemodialysis Patients With Uremic Pruritus</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Subject receive incenter hemodialysis â‰¥ 3 month currently schedule 3 time week . Subject selfcategorized Patient Assessed Disease Severity Scale Screening Subject meet standard care hemodialysis efficiency guideline three month prior complete Screening Have demonstrate pruritus intensity Itch NRS screen Male female least 18 year old time Screening Subject significant alteration dialysis regimen Screening Period Subject receive anticipated receive nocturnal dialysis home hemodialysis treatment study . Subject pruritus believe caused condition unrelated endstage renal disease Has history substance abuse within 6 month prior complete Screening Subject know drug allergy opioids Subject pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>uremic</keyword>
	<keyword>pruritus</keyword>
	<keyword>itch</keyword>
	<keyword>chronic itch</keyword>
	<keyword>nalbuphine</keyword>
</DOC>